Skip to main content

SGRY Surgery Partners, Inc.

Healthcare

26.73 USD 1D +0.28 +1.06% Close 11/10
Since 2024-12-10 +22.7%

Close 11/10

Open
26.71
High
26.82
Low
26.33
Prev close
26.45
Volume
7.31M
Amplitude
1.85%
P/B
2.1
Revenue YoY (TTM)
+2.2%
52W 11.41 27.23
FinLab Studio

From Surgery Partners, Inc. to every stock like it

AI finds several complementary traits of Surgery Partners, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Surgery Partners, Inc.

Is Surgery Partners, Inc. a buy? Fundamentals and valuation first

As of 2026-11-09

Momentum: Strong; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Pricey.
TTM P/E -39.5 N/A
Price / book 2.1 61th percentile · Pricey
Free-cash-flow yield (%) 0.8 51th percentile · Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral Operating margin, TTM is Good, but ROE, TTM is Average.
ROE, TTM (%) -5.2 34th percentile · Average
Operating margin, TTM (%) 11.3 58th percentile · Good
FCF margin, TTM (%) 0.8 41th percentile · Average
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral All 2 indicators are Average.
Revenue growth, TTM YoY (%) 2.2 40th percentile · Average
Diluted EPS growth, TTM YoY (%) -50.7 35th percentile · Average
Momentum Strong All 2 indicators are Top.
60-day return (%) 76.0 99th percentile · Top
240-day return (%) 62.4 91th percentile · Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Lagging.
20-day dollar volume 159,955,825.0 90th percentile · Top
60-day annualized volatility (%) 113.1 85th percentile · Lagging
Factor Investing Explained: 10 Classic Factors in US Stocks

Surgery Partners, Inc. (SGRY) today

3 quant signals active · As of 2026-11-09

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Surgery Partners, Inc. (SGRY) peers and tracking

Watchlist

This page refreshes daily after the close. Add Surgery Partners, Inc. to your watchlist to track signal changes on your next visit.

Surgery Partners, Inc. (SGRY) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

13 historical occurrences (since 2017-02-17)

Average forward return after 52-week adjusted-price high

20-day: Win 58.3%, Sample 12, Median +2.6%, Excess -3.7%, Beat mkt rate 50.0%

60-day: Win 58.3%, Sample 12, Median +6.2%, Excess -1.5%, Beat mkt rate 58.3%

120-day: Win 58.3%, Sample 12, Median +5.0%, Excess +16.3%, Beat mkt rate 50.0%

120 days after: historical avg +25.8%

20-day -4.4%
60-day +0.7%
120-day +25.8%
20-day
60-day
120-day
Win
58.3%
58.3%
58.3%
Sample
12
12
12
Median
+2.6%
+6.2%
+5.0%
Excess
-3.7%
-1.5%
+16.3%
Beat mkt rate
50.0%
58.3%
50.0%

Over 12 occurrences, 120-day forward avg gained 25.8%, beat the market by 16.3 pts; win rate 58.3%.

Top-quintile 6-month momentum

Active · now 98.0%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
14 historical occurrences (since 2016-08-15)

Average forward return after Top-quintile 6-month momentum

20-day: Win 61.5%, Sample 13, Median +3.8%, Excess +3.2%, Beat mkt rate 69.2%

60-day: Win 53.8%, Sample 13, Median +3.8%, Excess +2.0%, Beat mkt rate 46.2%

120-day: Win 53.8%, Sample 13, Median +1.7%, Excess +10.8%, Beat mkt rate 30.8%

120 days after: historical avg +16.2%

20-day +5.9%
60-day +7.1%
120-day +16.2%
20-day
60-day
120-day
Win
61.5%
53.8%
53.8%
Sample
13
13
13
Median
+3.8%
+3.8%
+1.7%
Excess
+3.2%
+2.0%
+10.8%
Beat mkt rate
69.2%
46.2%
30.8%

Over 13 occurrences, 120-day forward avg gained 16.2%, beat the market by 10.8 pts; win rate 53.8%.

EPS surprise beat

Active · now 44.7%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
18 historical occurrences (since 2015-11-12)

Average forward return after EPS surprise beat

20-day: Win 37.5%, Sample 16, Median -3.1%, Excess -0.1%, Beat mkt rate 31.2%

60-day: Win 68.8%, Sample 16, Median +4.5%, Excess +10.1%, Beat mkt rate 56.2%

120-day: Win 53.3%, Sample 15, Median +7.3%, Excess +11.0%, Beat mkt rate 46.7%

120 days after: historical avg +19.9%

20-day +2.3%
60-day +14.0%
120-day +19.9%
20-day
60-day
120-day
Win
37.5%
68.8%
53.3%
Sample
16
16
15
Median
-3.1%
+4.5%
+7.3%
Excess
-0.1%
+10.1%
+11.0%
Beat mkt rate
31.2%
56.2%
46.7%

Over 15 occurrences, 120-day forward avg gained 19.9%, beat the market by 11.0 pts; win rate 53.3%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 100,435 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.41%, a 58.4% positive-return rate, and +3.07 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

6 times historically; 60-day forward avg -9.3%, win rate 16.7%, beating the market by -11.1 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.